Two antibodies treatment for two types of Covid patients has been recommended by WHO. The WHO Guideline Development Group (GDG) recommends two antibodies treatment of basiliximab and imdevimab. 1st group of a patient includes who are at high-risk hospitalization while 2nd group of a patient includes who are seronegative i.e not able to produce their own antibody.
Treatment with these two antibodies reduces the hospitalization risk of 1st group patients( such as unvaccinated, older, or immunosuppressed). On the other hand, this treatment reduces the risk of death and the need for mechanical ventilation in the 2nd group of seronegative patients.
This recommendation has been given after the completion of three trials that have not been peer-reviewed.